Biotech startup Anexon Inc. raised $7 million in equity, according to the federal Securities & Exchange Commission.
The Cambridge, Mass.-based company, which is in stealth mode, filed three documents with the SEC for separate tiers of the fundraising round, each with a different minimum investment.
There were two filings for completed funding rounds, one for $3 million and another for $2 million. The latest sale of equity, which seeks to raise $12 million, began on Oct. 14 and has so far brought in $2 million.
Anexon is developing therapeutics for cardiovascular disease. The company launched in 2007 with a $500,000 seed investment from Cambridge-based life sciences venture firm Healthcare Ventures. Along with the Mayo Clinic, Healthcare Ventures firm is listed as an investor in the latest round.
Healthcare Ventures managing director Christopher Mirabelli is listed as a director and executive officer of Anexon on each of the filings. Vice chair of the Mayo Clinic Office of Intellectual Property Steven Van Nurden is also listed as a director.
